Cellectar Eyes EU Market, Advances Dual Cancer Drug Pipeline

FLORHAM PARK, N.J. – March 04, 2026 – Cellectar Biosciences is charting a decisive course toward commercialization, announcing significant regulatory and clinical progress for its targeted cancer therapies alongside its 2025 financial results. The late-stage biopharmaceutical company confirmed it is on track to submit its lead drug candidate, iopofosine I 131, for European approval in the third quarter of 2026, a move that could bring a new treatment option to patients with a rare blood cancer as early as 2027.

The announcement highlights a period of focused execution for the company, which is developing a new class of treatments based on its proprietary Phospholipid Drug Conjugate (PDC) platform. This technology is designed to act like a Trojan horse, delivering potent radioisotopes directly to cancer cells while sparing healthy tissue.

“2025 was a productive year for Cellectar, marked by disciplined execution across our pipeline and meaningful clinical, regulatory, and operational achievements,” said James Caruso, president and CEO of Cellectar. “As we look ahead to 2026, our momentum is building. We expect important clinical readouts, continued regulatory progress, and expansion of our next-generation Phospholipid Drug Conjugate (PDC) programs.”

A Pivotal Step Towards the European Market

Cellectar’s primary focus is securing a Conditional Marketing Authorization (CMA) from the European Medicines Agency (EMA) for iopofosine I 131 as a treatment for Waldenström Macroglobulinemia (WM), a slow-growing and incurable form of non-Hodgkin lymphoma. The CMA pathway is specifically designed to accelerate patient access to medicines that address significant unmet medical needs, allowing for approval based on a strong, albeit not fully comprehensive, data package, with a requirement to provide more complete data post-launch.

The company’s confidence is bolstered by prior guidance from the EMA’s Scientific Advice Working Party and a PRIority MEdicines (PRIME) designation, a program that provides enhanced regulatory support for promising drugs. The submission will be supported by the comprehensive dataset from the CLOVER WaM study, which demonstrated compelling efficacy in a heavily pretreated patient population.

Waldenström Macroglobulinemia affects a small but vulnerable patient population, with incidence rates in Europe as low as 1 in 263,000 persons per year. For these patients, particularly those who have relapsed or become resistant to existing treatments, new therapeutic options are critical. Iopofosine I 131, as a first-in-class radioconjugate, offers a novel mechanism of action that could fill a crucial gap in the current treatment paradigm.

Breakthroughs on the Home Front

While the European strategy advances, Cellectar is also solidifying its position in the United States. The company’s lead candidate has already received a coveted Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for relapsed or refractory WM. This designation is reserved for drugs that have shown preliminary evidence of substantial improvement over available therapies and serves to expedite their development and review.

More significantly, the FDA has recommended that Cellectar investigate iopofosine I 131 as a treatment for patients as early as the second line of therapy, specifically after treatment with Bruton's tyrosine kinase inhibitors (BTKis). BTKis are a standard of care for WM, but many patients eventually relapse, leaving them with few effective options. The CLOVER-WaM study data was particularly strong in this group, showing an overall response rate of 72%, a dramatic improvement over the typical 10% response rates seen with salvage therapies in this population. This recommendation could substantially expand the drug's potential market in the U.S. by moving it into an earlier treatment setting.

The Power of a Targeted Platform

Underpinning these clinical advances is Cellectar’s innovative Phospholipid Drug Conjugate (PDC) platform. The technology exploits the unique characteristics of cancer cell membranes, which readily absorb and retain the company's proprietary phospholipid ether molecules. By attaching a cytotoxic payload—in this case, a radioisotope—to these carriers, the platform enables the targeted delivery of treatment directly to tumors and their metastases.

Demonstrating the versatility of this platform, Cellectar also announced the initiation of a Phase 1b study for a second asset, CLR 125. This drug candidate uses the same PDC delivery system but carries a different radioisotope, iodine-125, designed to treat solid tumors. The initial study is focused on Triple Negative Breast Cancer (TNBC), an aggressive and difficult-to-treat form of breast cancer with limited targeted therapy options. Early data from this dose-finding study is anticipated by mid-2026 and will be a key test of the PDC platform's broader applicability beyond hematologic cancers.

Navigating the Financial Gauntlet

Alongside its clinical and regulatory milestones, Cellectar reported a sharpened focus on financial discipline. The company ended 2025 with $13.2 million in cash and cash equivalents, which it believes will fund operations into the third quarter of 2026. While operating at a loss is typical for a late-stage biotech, Cellectar significantly reduced its cash burn. The net loss for 2025 was $21.8 million, a stark decrease from $44.6 million in 2024.

This was achieved through substantial cuts in spending, with both Research and Development and General and Administrative expenses more than halved compared to the previous year. The company attributed this to reduced clinical study activity as the CLOVER WaM trial moved into its follow-up phase and a decrease in pre-commercialization efforts. This calculated financial management positions the company to direct its resources toward the most critical near-term goals: the European CMA submission and the advancement of its clinical pipeline. However, with a finite cash runway, the company will likely need to secure additional funding through investment or strategic partnerships to support its path to potential commercialization.